ClinicalTrials.gg
CompletedNCT04171414Updated Nov 17, 2021Results posted

A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis

A Phase 3 interventional study of CT-P17 SC AI (adalimumab) in Rheumatoid Arthritis, sponsored by Celltrion. Completed at 1 site in Poland. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-11-17.

Sponsored by Celltrion · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
67th of 87
62 · median 160
Started
2019
with 3 others
Phase 3
36 of 87
1 open now
Registered
81st of 87
by date

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 67th largest by enrollment, is one of 4 that started in 2019, is one of 36 in phase 3, and was the 81st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Clinical trial to evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis

Read the detailed description

CT-P17, containing the active ingredient adalimumab, is a recombinant humanized monoclonal antibody that is being developed as a similar biological medicinal product to Humira. The purpose of this study is to evaluate usability of subcutaneous auto-injector of CT-P17 in patients with moderate to severe rheumatoid arthritis.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patient aged 18 to 70 years, inclusive.
  • Patient must be able and willing to self-administer subcutaneous (SC) injections via auto injector (AI).

Exclusion criteria

Exclusion Criteria:

  • Patient who has previously received or licensed product; biologic or targeted synthetic disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis and/or a tumor necrosis factor (TNF) α inhibitor for any purposes.
  • Patient who has allergies to any of the of study drug or any other murine and human proteins, or patient with a to immunoglobulin products.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    "CT-P17 SC AI (adalimumab)"

    CT-P17 Subcutaneous(SC) Autoinjector(AI) (adalimumab)

    Biological: CT-P17 SC AI (adalimumab)

Interventions

06

What researchers measure

Primary outcomes

  1. The Usability as Assessed by Patients Rating Using PRE- and POST-Self-Injection Assessment Questionnaire (SIAQ) at Week 4

    The usability of CT-P17 Auto Injector is measured by participant using PRE- and POST-Self-injection Assessment Questionnaire (SIAQ) modules. The PRE-SIAQ module is a 7-item questionnaire and the POST-SIAQ module is a 27-item questionnaire that assesses feelings about injections, self-image, self-confidence (regarding self-administration), pain and skin reactions before after injection. Participants rated each item of the SIAQ on a 5-point (or 6-point) semantic Likert-type scal. (each item graded on a 5-point scale). \[Scores were transformed to Rate between 0 (worst) to 10 (best)\]

    Time frame: Week 4

Secondary outcomes

  1. Patient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24

    Time frame: Week 0

  2. Observer's Rating of Successful Self-injection Using Self-injection Assessment Checklist at Weeks 0, 2, 4, and 24

    Time frame: Week 0,2,4,24

  3. Mean for Actual Values and Change From Baseline in DAS28 (CRP and ESR)

    DAS28 (CRP) was calculated using the following formula: DAS28 (CRP) = 0.56 X SQRT(TJC28) + 0.28 X SQRT(SJC28) + 0.36 X ln(CRP+1) + 0.014 X GH on VAS + 0.96. DAS28 (CRP) provides a number on a scale from 0 to 10 with higher values indicating greater RA disease activity. DAS28 (ESR) was calculated using the following formula: DAS28 (CRP) = 0.56 X SQRT(TJC28) + 0.28 X SQRT(SJC28) + 0.36 X ln(ESR) + 0.014 X GH on VAS. DAS28 (ESR) provides a number on a scale from 0 to 10 with higher values indicating greater RA disease activity. Abbreviation: CRP, C-reactive protein; DAS28, Disease Activity Score using 28 joint counts; ESR, Erythrocyte sedimentation rate

    Time frame: Week 8,16,24

  4. Patient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24

    Time frame: Week 2

  5. Patient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24

    Time frame: Week 24

07

Results

Posted Nov 17, 2021

Participant flow

Participant flow — Overall Study
Milestone"CT-P17 SC AI (Adalimumab)"
Started62
Completed60
Not completed2
Withdrew: Death1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryThe Usability as Assessed by Patients Rating Using PRE- and POST-Self-Injection Assessment Questionnaire (SIAQ) at Week 4

The usability of CT-P17 Auto Injector is measured by participant using PRE- and POST-Self-injection Assessment Questionnaire (SIAQ) modules. The PRE-SIAQ module is a 7-item questionnaire and the POST-SIAQ module is a 27-item questionnaire that assesses feelings about injections, self-image, self-confidence (regarding self-administration), pain and skin reactions before after injection. Participants rated each item of the SIAQ on a 5-point (or 6-point) semantic Likert-type scal. (each item graded on a 5-point scale). \[Scores were transformed to Rate between 0 (worst) to 10 (best)\]

Time frame:
Week 4
Reported as:
Mean · scores on a scale
The Usability as Assessed by Patients Rating Using PRE- and POST-Self-Injection Assessment Questionnaire (SIAQ) at Week 4
scores on a scale"CT-P17 SC AI (Adalimumab)"
Feelings about self-injections (PRE)8.00 ± 2.131
Feelings about self-injections (POST)8.16 ± 2.036
Self-confidence (PRE)6.55 ± 1.859
Self-confidence (POST)7.07 ± 1.616
Self-image (POST)8.39 ± 2.079
Pain and skin reactions during or after the injection (POST)9.59 ± 0.968
Ease of use of the self-injection device (POST)8.70 ± 1.457
Satisfaction with self-injection (PRE)8.27 ± 1.669
Satisfaction with self-injection (POST)8.23 ± 1.191
SecondaryPatient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24
Time frame:
Week 0
Reported as:
Mean · scores on a scale
Patient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24
scores on a scale"CT-P17 SC AI (Adalimumab)"
Feelings about self-injections (PRE)7.39 ± 2.437
Feelings about self-injections (POST)8.04 ± 2.086
Self-confidence (PRE)5.22 ± 2.272
Self-confidence (POST)6.18 ± 2.518
Self-image (POST)8.35 ± 2.306
Pain and skin reactions during or after the injection (POST)9.48 ± 1.152
Ease of use of the self-injection device (POST)8.40 ± 1.531
Satisfaction with self-injection (PRE)6.15 ± 1.682
Satisfaction with self-injection (POST)8.00 ± 1.250
SecondaryObserver's Rating of Successful Self-injection Using Self-injection Assessment Checklist at Weeks 0, 2, 4, and 24
Time frame:
Week 0,2,4,24
Reported as:
Count of participants · Participants
Observer's Rating of Successful Self-injection Using Self-injection Assessment Checklist at Weeks 0, 2, 4, and 24
Participants"CT-P17 SC AI (Adalimumab)"
Week 0, Successful Self-Injection62
Week 0, Overall Successful Self-Injection62
Week 2, Successful Self-Injection62
Week 2, Overall Successful Self-Injection62
Week 4, Successful Self-Injection62
Week 4, Overall Successful Self-Injection62
Week 24, Successful Self-Injection60
Week 24, Overall Successful Self-Injection60
SecondaryMean for Actual Values and Change From Baseline in DAS28 (CRP and ESR)

DAS28 (CRP) was calculated using the following formula: DAS28 (CRP) = 0.56 X SQRT(TJC28) + 0.28 X SQRT(SJC28) + 0.36 X ln(CRP+1) + 0.014 X GH on VAS + 0.96. DAS28 (CRP) provides a number on a scale from 0 to 10 with higher values indicating greater RA disease activity. DAS28 (ESR) was calculated using the following formula: DAS28 (CRP) = 0.56 X SQRT(TJC28) + 0.28 X SQRT(SJC28) + 0.36 X ln(ESR) + 0.014 X GH on VAS. DAS28 (ESR) provides a number on a scale from 0 to 10 with higher values indicating greater RA disease activity. Abbreviation: CRP, C-reactive protein; DAS28, Disease Activity Score using 28 joint counts; ESR, Erythrocyte sedimentation rate

Time frame:
Week 8,16,24
Reported as:
Mean · scores on a scale
Mean for Actual Values and Change From Baseline in DAS28 (CRP and ESR)
scores on a scale"CT-P17 SC AI (Adalimumab)"
CRP, Baseline5.248 ± 0.8415
CRP, Week 8, Change from baseline-2.560 ± 1.1223
CRP, Week 16, Change from baseline-2.795 ± 1.2381
CRP, Week 24, Change from baseline-3.111 ± 1.1109
ESR, Baseline6.190 ± 0.7360
ESR, Week 8, Change from baseline-3.287 ± 1.3525
ESR, Week 16, Change from baseline-3.495 ± 1.4695
ESR, Week 24, Change from baseline-3.799 ± 1.4287
SecondaryPatient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24
Time frame:
Week 2
Reported as:
Mean · scores on a scale
Patient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24
scores on a scale"CT-P17 SC AI (Adalimumab)"
Feelings about self-injections (PRE)7.93 ± 2.175
Feelings about self-injections (POST)8.08 ± 2.110
Self-confidence (PRE)6.61 ± 2.007
Self-confidence (POST)6.67 ± 1.811
Self-image (POST)8.27 ± 2.245
Pain and skin reactions during or after the injection (POST)9.64 ± 0.693
Ease of use of the self-injection device (POST)8.34 ± 1.698
Satisfaction with self-injection (PRE)7.78 ± 2.128
Satisfaction with self-injection (POST)8.16 ± 1.177
SecondaryPatient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24
Time frame:
Week 24
Reported as:
Mean · scores on a scale
Patient's Rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24
scores on a scale"CT-P17 SC AI (Adalimumab)"
Feelings about self-injections (PRE)8.88 ± 2.034
Feelings about self-injections (POST)8.97 ± 1.888
Self-confidence (PRE)7.21 ± 1.556
Self-confidence (POST)7.44 ± 1.840
Self-image (POST)9.04 ± 1.533
Pain and skin reactions during or after the injection (POST)9.60 ± 0.841
Ease of use of the self-injection device (POST)9.35 ± 1.057
Satisfaction with self-injection (PRE)8.83 ± 1.868
Satisfaction with self-injection (POST)8.95 ± 1.023

Adverse events

Collected over Adverse events were assessed from the date the patient signed the ICF until EOS/ED visit. (up to week 28, including 4 weeks of follow-up period). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
"CT-P17 SC AI (Adalimumab)"1/62 (1.6%)3/62 (4.8%)20/62 (32.3%)
Most frequent serious events
Most frequent serious events
Event"CT-P17 SC AI (Adalimumab)"
Lower gastrointestinal haemorrhageGastrointestinal disorders1/62
Tooth infectionInfections and infestations1/62
Cervical polypReproductive system and breast disorders1/62
Most frequent other events
Most frequent other events
Event"CT-P17 SC AI (Adalimumab)"
Upper respiratory tract infectionInfections and infestations13/62
Urinary tract infectionInfections and infestations3/62
DiarrhoeaGastrointestinal disorders2/62
HeadacheNervous system disorders2/62
HyperbilirubinaemiaHepatobiliary disorders2/62
Influenza like illnessGeneral disorders2/62
Injection site reactionGeneral disorders2/62
NasopharyngitisInfections and infestations2/62
PharyngitisInfections and infestations2/62

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)"CT-P17 SC AI (Adalimumab)"
<=18 years0
Between 18 and 65 years56
>=65 years6
Age, Continuous
Age, Continuous(Years)"CT-P17 SC AI (Adalimumab)"
Median54.0 (19 to 70)
Sex: Female, Male
Sex: Female, Male(Participants)"CT-P17 SC AI (Adalimumab)"
Female42
Male20
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)"CT-P17 SC AI (Adalimumab)"
Hispanic or Latino0
Not Hispanic or Latino62
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)"CT-P17 SC AI (Adalimumab)"
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White62
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)"CT-P17 SC AI (Adalimumab)"
Poland62
08

Study locations

1 site
  • Nasz Lekarz Osrodek Badan Klinicznych
    Bydgoszcz, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Nov 2019, 1 month.

Results were first posted in Nov 2021, 2 years after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 1 month is below that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2019
First posted
Nov 20, 2019
StartActual
Sep 9, 2019
Primary completionActual
Nov 4, 2019
CompletionActual
Apr 24, 2020
Results first posted
Nov 17, 2021
Last update
Nov 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04171414
Lead sponsor
Celltrion
Collaborators
PPD DEVELOPMENT, LP
Responsible party
Sponsor
First posted
Nov 20, 2019
Start date
Sep 9, 2019
Primary completion
Nov 4, 2019
Completion
Apr 24, 2020
Results posted
Nov 17, 2021
Last update
Nov 17, 2021

Study contacts

MinJi Ma
study chair · Celltrion, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion